Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Feasibility of Establishing a Comprehensive Yoga Program and its Dose-Effect Relationship on Cardiovascular Risk Factors and Wellness Parameters: A Pilot Study.

Chinnaiyan KM, DePetris AM, Boura JA, Stakich-Alpirez K, Billecke SS.

Int J Yoga Therap. 2015;25(1):135-40. doi: 10.17761/1531-2054-25.1.135.

PMID:
26667296
2.

Injury or activity-related pain sustained by a population of at-risk women during a 6-month exercise program.

Billecke SS, Marcovitz PA, Donnelly M, Franklin BA.

Phys Sportsmed. 2013 May;41(2):7-14. doi: 10.3810/psm.2013.05.2007.

PMID:
23703512
3.

Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertension.

Billecke SS, Marcovitz PA.

Vasc Health Risk Manag. 2013;9:95-104. doi: 10.2147/VHRM.S40963. Epub 2013 Mar 16. Review.

4.

Potential treatment influences and mechanisms related to asymmetric dimethylarginine control in heart failure.

Billecke SS, D'Alecy LG, Marcovitz PA.

J Am Coll Cardiol. 2012 Sep 4;60(10):948-9; author reply 949. doi: 10.1016/j.jacc.2012.04.044. No abstract available.

5.

Putting the benefits and risks of aerobic exercise in perspective.

Franklin BA, Billecke S.

Curr Sports Med Rep. 2012 Jul-Aug;11(4):201-8. doi: 10.1249/JSR.0b013e31825dabd4.

PMID:
22777331
6.

Nitric oxide synthase, ADMA, SDMA, and nitric oxide activity in the paraventricular nucleus throughout the etiology of renal wrap hypertension.

Northcott CA, Billecke S, Craig T, Hinojosa-Laborde C, Patel KP, Chen AF, D'Alecy LG, Haywood JR.

Am J Physiol Heart Circ Physiol. 2012 Jun 1;302(11):H2276-84. doi: 10.1152/ajpheart.00562.2011. Epub 2012 Mar 23.

7.

Aliskiren/amlodipine combination for the treatment of hypertension.

Billecke SS, Marcovitz PA.

Drugs Today (Barc). 2011 Jun;47(6):403-17. doi: 10.1358/dot.2011.47.6.1603505.

PMID:
21695283
8.

Pitfalls in the assessment of PON1 status in clinical populations.

Billecke SS, Teiber JF.

Fertil Steril. 2011 Jun 30;95(8):e63; author reply e64. doi: 10.1016/j.fertnstert.2011.04.016. Epub 2011 May 4. No abstract available.

PMID:
21536277
9.

Pheochromocytoma presenting with Takotsubo syndrome.

Marcovitz PA, Czako P, Rosenblatt S, Billecke SS.

J Interv Cardiol. 2010 Oct;23(5):437-42. doi: 10.1111/j.1540-8183.2010.00551.x. Review.

PMID:
21029177
10.

Massive quantities of asymmetric dimethylarginine (ADMA) are incorporated in red blood cell proteins and may be released by proteolysis following hemolytic stress.

D'Alecy LG, Billecke SS.

Blood Cells Mol Dis. 2010 Jun 15;45(1):40. doi: 10.1016/j.bcmd.2010.03.004. Epub 2010 Apr 8. No abstract available.

PMID:
20381387
11.

Usefulness of breast arterial calcium detected on mammography for predicting coronary artery disease or cardiovascular events in women with angina pectoris and/or positive stress tests.

Penugonda N, Billecke SS, Yerkey MW, Rebner M, Marcovitz PA.

Am J Cardiol. 2010 Feb 1;105(3):359-61. doi: 10.1016/j.amjcard.2009.09.039.

PMID:
20102948
12.

Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease.

Billecke SS, D'Alecy LG, Platel R, Whitesall SE, Jamerson KA, Perlman RL, Gadegbeku CA.

Nephrol Dial Transplant. 2009 Feb;24(2):489-96. doi: 10.1093/ndt/gfn500. Epub 2008 Sep 15.

13.

Estrogen esters as substrates for human paraoxonases.

Teiber JF, Billecke SS, La Du BN, Draganov DI.

Arch Biochem Biophys. 2007 May 1;461(1):24-9. Epub 2007 Mar 8.

PMID:
17412306
14.

Contribution of whole blood to the control of plasma asymmetrical dimethylarginine.

Billecke SS, Kitzmiller LA, Northrup JJ, Whitesall SE, Kimoto M, Hinz AV, D'Alecy LG.

Am J Physiol Heart Circ Physiol. 2006 Oct;291(4):H1788-96. Epub 2006 Apr 21.

15.

Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats.

Carello KA, Whitesall SE, Lloyd MC, Billecke SS, D'Alecy LG.

Am J Physiol Heart Circ Physiol. 2006 Jan;290(1):H209-16. Epub 2005 Aug 19.

16.

Ubiquitination and degradation of neuronal nitric-oxide synthase in vitro: dimer stabilization protects the enzyme from proteolysis.

Dunbar AY, Kamada Y, Jenkins GJ, Lowe ER, Billecke SS, Osawa Y.

Mol Pharmacol. 2004 Oct;66(4):964-9. Epub 2004 Jul 2.

PMID:
15235101
17.

The role of hsp90 in heme-dependent activation of apo-neuronal nitric-oxide synthase.

Billecke SS, Draganov DI, Morishima Y, Murphy PJ, Dunbar AY, Pratt WB, Osawa Y.

J Biol Chem. 2004 Jul 16;279(29):30252-8. Epub 2004 May 19.

18.

Metabolism-based inactivation of neuronal nitric-oxide synthase by components of cigarette and cigarette smoke.

Demady DR, Lowe ER, Everett AC, Billecke SS, Kamada Y, Dunbar AY, Osawa Y.

Drug Metab Dispos. 2003 Jul;31(7):932-7.

PMID:
12814971
19.

Proteolytic degradation of nitric oxide synthase: effect of inhibitors and role of hsp90-based chaperones.

Osawa Y, Lowe ER, Everett AC, Dunbar AY, Billecke SS.

J Pharmacol Exp Ther. 2003 Feb;304(2):493-7. Review.

PMID:
12538799
20.

hsp90 is required for heme binding and activation of apo-neuronal nitric-oxide synthase: geldanamycin-mediated oxidant generation is unrelated to any action of hsp90.

Billecke SS, Bender AT, Kanelakis KC, Murphy PJ, Lowe ER, Kamada Y, Pratt WB, Osawa Y.

J Biol Chem. 2002 Jun 7;277(23):20504-9. Epub 2002 Mar 28.

21.

Rabbits possess a serum paraoxonase polymorphism similar to the human Q192R.

Watson CE, Draganov DI, Billecke SS, Bisgaier CL, La Du BN.

Pharmacogenetics. 2001 Mar;11(2):123-34.

PMID:
11266077
22.

Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals.

La Du BN, Billecke S, Hsu C, Haley RW, Broomfield CA.

Drug Metab Dispos. 2001 Apr;29(4 Pt 2):566-9.

PMID:
11259353
23.

Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters.

Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, La Du BN.

Drug Metab Dispos. 2000 Nov;28(11):1335-42.

PMID:
11038162
24.

Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation.

Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN.

J Biol Chem. 2000 Oct 27;275(43):33435-42.

25.

Increased plasma cholinesterase activity and mivacurium resistance: report of a family.

Naguib M, Gomaa M, Samarkandi AH, Bevan DR, Akkielah AK, Watson C, Billecke S, La Du BN Jr.

Anesth Analg. 1999 Dec;89(6):1579-82. No abstract available.

PMID:
10589654
26.

Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity.

Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN.

Arterioscler Thromb Vasc Biol. 1999 Sep;19(9):2214-25.

PMID:
10479665
27.

On the physiological role(s) of the paraoxonases.

La Du BN, Aviram M, Billecke S, Navab M, Primo-Parmo S, Sorenson RC, Standiford TJ.

Chem Biol Interact. 1999 May 14;119-120:379-88. Review.

PMID:
10421474
28.

Characterization of a soluble mouse liver enzyme capable of hydrolyzing diisopropyl phosphorofluoridate.

Billecke SS, Primo-Parmo SL, Dunlop CS, Doorn JA, La Du BN, Broomfield CA.

Chem Biol Interact. 1999 May 14;119-120:251-6.

PMID:
10421459
29.

Properties of the retained N-terminal hydrophobic leader sequence in human serum paraoxonase/arylesterase.

Sorenson RC, Aviram M, Bisgaier CL, Billecke S, Hsu C, La Du BN.

Chem Biol Interact. 1999 May 14;119-120:243-9.

PMID:
10421458
30.

Evidence that several conserved histidine residues are required for hydrolytic activity of human paraoxonase/arylesterase.

Doorn JA, Sorenson RC, Billecke SS, Hsu C, La Du BN.

Chem Biol Interact. 1999 May 14;119-120:235-41.

PMID:
10421457
31.

Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans.

Haley RW, Billecke S, La Du BN.

Toxicol Appl Pharmacol. 1999 Jun 15;157(3):227-33.

PMID:
10373407
32.

Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants.

Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, Newton RS, La Du B.

Free Radic Biol Med. 1999 Apr;26(7-8):892-904.

PMID:
10232833
33.

Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R.

Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Hsu C, Dunlop C, La Du B.

Arterioscler Thromb Vasc Biol. 1998 Oct;18(10):1617-24.

PMID:
9763535

Supplemental Content

Loading ...
Support Center